NIPH Clinical Trials Search

JAPANESE
国立保健医療科学院
JRCT ID: jRCT1050230125

Registered date:09/11/2023

Multi-institutional observational study of dermatologic events sssociated with enfortumab vedotin

Basic Information

Recruitment status Recruiting
Health condition(s) or Problem(s) studiedUrothelila carcinoma
Date of first enrollment09/11/2023
Target sample size300
Countries of recruitment
Study typeObservational
Intervention(s)

Outcome(s)

Primary OutcomeDetails of dermatological evens after enfortumab vedotin administration (frequency, timing, location)
Secondary Outcome

Key inclusion & exclusion criteria

Age minimumNot applicable
Age maximumNot applicable
GenderBoth
Include criteriaPatients with unresectable or metastatic urothelial carcinoma who received enfortumab vedotin between January 1, 2020 and May 31, 2023 at the Department of Urology, Kyoto University Hospital and at participating institutions in the multicenter study.
Exclude criteriaNot available

Related Information

Contact

Public contact
Name YUKI KITA
Address Kyotoshi Sakyouku Syogoinkawaharacyo 54 Japan 606-8507
Telephone +81-75-751-3337
E-mail kitayuki@kuhp.kyoto-u.ac.jp
Affiliation Kyoto University Hospital
Scientific contact
Name Yuki Kita
Address Kyoto-shi Sakyo-ku Shogoinkawahara-cho 54 Kyoto Japan 606-8507
Telephone +81-75-751-3337
E-mail kitayuki@kuhp.kyoto-u.ac.jp
Affiliation Kyoto University Hospital